These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Erdheim-Chester disease. Starkebaum G; Hendrie P Best Pract Res Clin Rheumatol; 2020 Aug; 34(4):101510. PubMed ID: 32305313 [TBL] [Abstract][Full Text] [Related]
9. Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib. Salama H; Fahed Alzayed M; Alharbi KG; Khattak Z; Omer MH; Tahir L; ALhejazi A Am J Case Rep; 2022 Feb; 23():e935090. PubMed ID: 35171900 [TBL] [Abstract][Full Text] [Related]
10. Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review. Aggarwal A; Taychert M; Hasanin L; Doll D; Basuino MG; Hasanein H Oncology (Williston Park); 2023 Jul; 37(7):298-302. PubMed ID: 37499251 [TBL] [Abstract][Full Text] [Related]
11. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238 [TBL] [Abstract][Full Text] [Related]
12. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia]. Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028 [TBL] [Abstract][Full Text] [Related]
14. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476 [TBL] [Abstract][Full Text] [Related]
15. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768 [TBL] [Abstract][Full Text] [Related]
16. An effective treatment in Erdheim Chester disease: vemurafenib: a case report. Bozan E; Darçın T; Yaman S; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F J Med Case Rep; 2023 Oct; 17(1):426. PubMed ID: 37821987 [TBL] [Abstract][Full Text] [Related]
17. Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports. Qiao J; Ma R; Peng X; He W World J Surg Oncol; 2023 Jul; 21(1):233. PubMed ID: 37525276 [TBL] [Abstract][Full Text] [Related]
18. Multisystem Erdheim-Chester disease presenting with pericardial effusion confirmed by the effusion cytology specimen. Dai S; Su X; Liu WP; Wu Y Cardiovasc Pathol; 2024; 70():107625. PubMed ID: 38417471 [TBL] [Abstract][Full Text] [Related]
19. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. Saunders IM; Goodman AM; Kurzrock R Oncologist; 2020 Feb; 25(2):e386-e390. PubMed ID: 32043767 [TBL] [Abstract][Full Text] [Related]
20. Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series. Mazor RD; Manevich-Mazor M; Kesler A; Aizenstein O; Eshed I; Jaffe R; Pessach Y; Goldberg I; Sprecher E; Yaish I; Gural A; Ganzel C; Shoenfeld Y BMC Med; 2014 Dec; 12():221. PubMed ID: 25434739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]